Asset Details
Do you wish to reserve the book?
TGF-beta signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
TGF-beta signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome
Do you wish to request the book?
TGF-beta signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
TGF-beta signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome
2019
Overview
Shwachman-Diamond syndrome (SDS) is a rare and clinically heterogeneous bone marrow (BM) failure syndrome caused by mutations in the Shwachman-Bodian-Diamond syndrome (SBDS) gene. Although SDS was described more than 50 years ago, its molecular pathogenesis is poorly understood due, in part, to the rarity and heterogeneity of the affected hematopoietic progenitors. To address this, we used single-cell RNA sequencing to profile scant hematopoietic stem and progenitor cells from patients with SDS. We generated a single-cell map of early lineage commitment and found that SDS hematopoiesis was left-shifted with selective loss of granulocyte-monocyte progenitors. Transcriptional targets of transforming growth factor beta (TGF-[beta]) were dysregulated in SDS hematopoietic stem cells and multipotent progenitors, but not in lineage-committed progenitors. TGF-[beta] inhibitors (AVID200 and SD208) increased hematopoietic colony formation of SDS patient BM. Finally, TGF-[beta]3 and other TGF-[beta] pathway members were elevated in SDS patient blood plasma. These data establish the TGF-[beta] pathway as a candidate biomarker and therapeutic target in SDS and translate insights from single-cell biology into a potential therapy.
Publisher
American Society for Clinical Investigation
